Myelofibrosis

Incyte to Provide Update on Clinical Programs at Cowen Health Care Conference

Published in Hematology Week, March 31st, 2008

Incyte Corporation (Nasdaq:INCY) will announce at the Cowen and Company 28th Annual Health Care Conference results from its initial meeting with the U.S. Food & Drug Administration (FDA) regarding the development of its lead JAK inhibitor, INCB18424, for myelofibrosis.

Paul Friedman, M.D., Incyte's President and CEO, stated, "We had a successful meeting with the FDA where we discussed the design of the registration studies of INCB18424 for myelofibrosis. We've reached agreement on the type of endpoints that will support approval and we will not be required to demonstrate improved survival or normalization of cell counts in the blood or bone marrow. Based on the...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Hematology Week

Source: Hematology Week (2008-03-31)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry